Rahul D Jawarkar
Overview
Explore the profile of Rahul D Jawarkar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
58
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Masand V, Patil M, Al-Hussain S, Samad A, Rastija V, Jawarkar R, et al.
Chem Biol Drug Des
. 2025 Feb;
105(2):e70060.
PMID: 39912316
Despite advancements in molecular design rules and understanding biochemical processes, the field of drug design and discovery seeks to minimize the number and duration of synthesis-testing cycles to convert lead...
2.
Jawarkar R, Mali S, Deshmukh P, Ingle R, Al-Hussain S, Al-Mutairi A, et al.
J Mol Graph Model
. 2024 Dec;
135():108915.
PMID: 39729811
The work being presented now combines severe gradient boosting with Shapley values, a thriving merger within the field of explainable artificial intelligence. We also use a genetic algorithm to analyse...
3.
Batool Z, Ullah S, Khan A, Mali S, Gurav S, Jawarkar R, et al.
Sci Rep
. 2024 Oct;
14(1):25754.
PMID: 39468115
Tyrosinase is an enzyme crucial for the progression of melanogenesis. Immoderate production of melanin may be the cause of hyperpigmentation and darkening leading to skin diseases. Tyrosinase is the most...
4.
Shah S, Chaple D, Masand V, Jawarkar R, Chaudhari S, Abiramasundari A, et al.
Sci Rep
. 2024 Sep;
14(1):20740.
PMID: 39237650
No abstract available.
5.
Shah S, Chaple D, Masand V, Jawarkar R, Chaudhari S, Abiramasundari A, et al.
Sci Rep
. 2024 Jul;
14(1):15991.
PMID: 38987327
Cardiovascular diseases, including heart failure, stroke, and hypertension, affect 608 million people worldwide and cause 32% of deaths. Combination therapy is required in 60% of patients, involving concurrent Renin-Angiotensin-Aldosterone-System (RAAS)...
6.
Naseem S, Oneto A, Ullah S, Fatima S, Mali S, Jawarkar R, et al.
Int J Biol Macromol
. 2024 Jul;
275(Pt 1):133571.
PMID: 38960243
Prolyl oligopeptidase (POP) is a compelling therapeutic target associated with aging and neurodegenerative disorders due to its pivotal role in neuropeptide processing. Despite initial promise demonstrated by early-stage POP inhibitors,...
7.
Masand V, Al-Hussain S, Alzahrani A, Al-Mutairi A, Alqahtani A, Samad A, et al.
Expert Opin Drug Discov
. 2024 Jun;
19(8):991-1009.
PMID: 38898679
Background: Despite the progress in comprehending molecular design principles and biochemical processes associated with thrombin inhibition, there is a crucial need to optimize efforts and curtail the recurrence of synthesis-testing...
8.
Ullah S, Ullah A, Waqas M, Ahsan Halim S, Pasha A, Shafiq Z, et al.
Sci Rep
. 2024 May;
14(1):12588.
PMID: 38822113
The COVID-19 has had a significant influence on people's lives across the world. The viral genome has undergone numerous unanticipated changes that have given rise to new varieties, raising alarm...
9.
Salem M, Alqahtani A, Mali S, Alshwyeh H, Jawarkar R, Altamimi A, et al.
Future Med Chem
. 2024 May;
16(11):1053-1073.
PMID: 38708686
This study focused on designing and synthesizing novel derivatives of 3,5,8-trisubstituted coumarin. The synthesized compounds, particularly compound , exhibited significant cytotoxic effects on MCF-7 cells, surpassing staurosporine, and reduced toxicity...
10.
Alharthy R, Khalid S, Fatima S, Ullah S, Khan A, Mali S, et al.
Arch Pharm (Weinheim)
. 2024 Apr;
357(8):e2400140.
PMID: 38687119
Diabetes is a serious metabolic disorder affecting individuals of all age groups and prevails globally due to the failure of previous treatments. This study aims to address the most prevalent...